Cambridge Innovation Capital
No summary available yet.
CIC has genuinely unique deal flow through their exclusive Cambridge University relationship - this isn't marketing fluff, they literally have privileged access to the best IP coming out of one of the world's top research universities. Their track record speaks for itself: Bicycle Therapeutics IPO on NASDAQ, CMR Surgical unicorn, Gyroscope sold to Novartis for $1.5B, plus solid exits like Inivata ($390M) and PetMedix ($285M). Williamson brings serious credibility - 20 years US VC experience and co-chaired the UK government's university spinout review, so he knows the ecosystem inside out. Their Entrepreneur in Residence program is actually working - they're co-founding companies like Immutrin (just raised £65M from Frazier Life Sciences) by pairing seasoned operators with Cambridge academics. The downside? You're essentially betting on Cambridge staying relevant in deep tech, and they're very UK-focused if you want Silicon Valley-style growth.
- —Best for: Cambridge-linked deep tech/life sciences founders with serious IP
- —Watch out for: Very Cambridge-centric focus limits global expansion support
- —Known for: Genuine university access advantage and strong life sciences exits
Born out of a unique relationship with the University of Cambridge, CIC maintains privileged access to the university's most inspiring ideas and people in life sciences and deep tech. As a preferred investor for the University of Cambridge, they have unparalleled access to investment opportunities in the ecosystem. Their commercial objective is creating value, but their motivation is broader - driven by a desire to use expertise to support companies and positively impact society.
Primarily Series A focused with their main fund, but they've added a growth-stage Opportunity Fund that targets later-stage companies. Their bread and butter is seed to Series A in Cambridge-linked deep tech and life sciences. Sectors include artificial intelligence, quantum technologies, semiconductors, robotics, autonomous systems, therapeutics, medtech, diagnostics, digital health, and genomics/proteomics.
Spent 20 years in US venture capital at Physic Ventures (San Francisco) and True North Venture Partners (Chicago) before returning to UK to lead CIC in 2016. PhD in Physics from Cambridge, MBA from UC Berkeley. Recently co-chaired the UK government's review of University Spinouts and chaired the BVCA venture capital committee.
Previously Senior Associate at Sofinnova Partners. Active in Women In Biotech panels discussing breaking down double standards in investment. One of the core investment partners alongside Williamson.
Listed as a key partner at CIC. Invests across BioTech, AI, DeepTech, and FinTech with sweet spot around £3.3M investments. Part of the core investment team at the firm.
Have a specific question about Cambridge Innovation Capital?
Ask Bernie →